Sangamo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 08, 2023 at 04:01 pm EDT
Share
Sangamo Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 6.84 million compared to USD 29.38 million a year ago. Net loss was USD 114.51 million compared to USD 43.17 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 0.29 a year ago.
For the six months, sales was USD 164.79 million compared to USD 57.61 million a year ago. Net loss was USD 93.37 million compared to USD 87.15 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.59 a year ago.
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
SANGAMO THERAPEUTICS, INC. 
